Meeting
2018 Genitourinary Cancers Symposium
Whole blood AR-V7 and AR-V9 mRNA expression and treatment response in metastatic castrate-resistant prostate cancer (mCRPC).
Authors
Edmond Michael Kwan
Monash Health, Clayton, Australia
Edmond Michael Kwan , Sarah To , Heidi Fettke , Andrew Michael Mant , Maria Docanto , Luciano Martelotto , Patricia Bukczynska , Nicole Ng , Lisa-Jane Graham , Phillip Parente , Carmel Jo Pezaro , Kate Lynette Mahon , Lisa Horvath , Tilman Todenhöfer , Arun Azad
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 252)
DOI
10.1200/JCO.2018.36.6_suppl.252
Abstract #
252
Poster Bd #
M6
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Radiographic paradoxical response in patients with metastatic castrate-resistant prostate cancer (mCRPC) undergoing treatment with second-generation hormone therapy (second-HT).
First Author: Jamal Alamiri
Poster
2020 Genitourinary Cancers Symposium
Association of high plasma glutamine levels with outcome in metastatic castration-resistant prostate (mCRPC) patients treated with taxanes.
First Author: Veronica Pereira Diaz
Poster
2019 ASCO Annual Meeting
Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer (mCRPC): Updated analysis of the adaptive abiraterone (abi) study (NCT02415621).
First Author: Jingsong Zhang
Poster
2017 ASCO Annual Meeting
Combination of PDL-1 and PARP inhibition in an unselected population with metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Fatima Karzai